Study selection process. حسب Juan Gu (288925)

"…A period of 10–20 years since the last birth also showed a decreased risk (OR=0.867; 95% CI:0.747–1.007), whereas more than 20 years since the last birth was associated with an increased risk (OR = 1.304; 95% CI: 1.111–1.530).…"

Newly occurring LTSA-MD cases in workers for over a month. حسب Yasuhiko Deguchi (3167955)

The Ishihara test for colourblindness [41] encompasses stimuli that can determine the degree and type of colourblindness a person has. حسب Marcel F. Hinss (14675457)

Starvation improves locomotory capacity and decreases the number of α-synuclein-YFP aggregates of transgenic <i>C. elegans</i> through LMP-1 dependent mechanism. حسب María Gallardo-Campos (22170919)

Results of two-way ANCOVA for <i>InR</i> and <i>Thor</i> expression differences by temperature and nutritional state interaction with <i>FoxO</i> as a covariate. حسب Tucker Hopkins (20790529)

Table 1_Dual variants of uncertain significance in a case of hyper-IgM syndrome: implications for diagnosis and management.docx حسب Nourhen Agrebi (14151222)

"…</p>Methods<p>We present immunological and genetic analysis of a Tunisian patient with two homozygous variants of uncertain significance (VUSs) in the IKBKB and AICDA genes, suspected of causing hyper-IgM and immune deficiency. …"

(A and B) ChIP-qPCR analysis of HSF2 binding to the indicated KSHV genomic regions expressed as % of input in KSHV infected latent (A) and lytic (B) cells. حسب Lorenza Cutrone (21144285)

Proportion of first-time testers by key population group. حسب Bao Vu Ngoc (14551955)

الموضوعات:

Comparative cost analysis of HCVST and PL-HCVT models (in US$). حسب Bao Vu Ngoc (14551955)

الموضوعات:

Incremental costs per month for different HCV testing models. حسب Bao Vu Ngoc (14551955)

الموضوعات:

Characteristics of propensity score matched groups. حسب Clemens Plattner (21567706)

الموضوعات:

Comparative costs of HCVST and PL-HCVT models in sensitivity analysis (in US$). حسب Bao Vu Ngoc (14551955)

الموضوعات:

HCV positivity rate by key population group opting for HCVST and standard HCVT. حسب Bao Vu Ngoc (14551955)

الموضوعات:

Characteristics of propensity score matched groups. حسب Clemens Plattner (21567706)

الموضوعات:

Demographic characteristics of study participants. حسب Bao Vu Ngoc (14551955)

الموضوعات:

Proportion of first-time HCV testers by testing model. حسب Bao Vu Ngoc (14551955)

الموضوعات:

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer حسب Kaizhao Hu (15670612)

"…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …"

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer حسب Kaizhao Hu (15670612)

"…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …"

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer حسب Kaizhao Hu (15670612)

"…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …"

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer حسب Kaizhao Hu (15670612)

"…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …"